Shares of Novartis AG (NYSE:NVS) have received a consensus rating of “Hold” from the eighteen research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $80.42.
A number of analysts have commented on NVS shares. Vetr upgraded shares of Novartis AG from a “buy” rating to a “strong-buy” rating and set a $85.25 price target for the company in a research note on Wednesday, March 8th. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research note on Thursday, March 23rd. BNP Paribas lowered shares of Novartis AG from a “neutral” rating to an “underperform” rating in a research report on Tuesday, March 7th. Barclays PLC assumed coverage on shares of Novartis AG in a research report on Tuesday, March 7th. They set an “underweight” rating on the stock. Finally, Liberum Capital assumed coverage on shares of Novartis AG in a report on Thursday, March 9th. They issued a “buy” rating on the stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Causeway Capital Management LLC boosted its position in shares of Novartis AG by 6.3% in the first quarter. Causeway Capital Management LLC now owns 338,149 shares of the company’s stock worth $25,114,000 after buying an additional 20,131 shares during the last quarter. Laurel Wealth Advisors Inc. boosted its position in shares of Novartis AG by 7.9% in the first quarter. Laurel Wealth Advisors Inc. now owns 18,553 shares of the company’s stock worth $1,377,000 after buying an additional 1,352 shares during the last quarter. Columbia Partners L L C Investment Management boosted its position in shares of Novartis AG by 12.1% in the first quarter. Columbia Partners L L C Investment Management now owns 15,200 shares of the company’s stock worth $1,128,000 after buying an additional 1,640 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Novartis AG during the first quarter worth approximately $3,428,000. Finally, Sowell Financial Services LLC boosted its position in shares of Novartis AG by 118.6% in the first quarter. Sowell Financial Services LLC now owns 3,358 shares of the company’s stock worth $273,000 after buying an additional 1,822 shares during the last quarter. Institutional investors own 11.37% of the company’s stock.
Novartis AG (NVS) traded up 0.75% during midday trading on Monday, hitting $81.44. The company had a trading volume of 1,139,392 shares. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58. The stock has a market cap of $192.65 billion, a price-to-earnings ratio of 30.62 and a beta of 0.76. The company’s 50 day moving average is $80.16 and its 200 day moving average is $75.15.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, April 25th. The company reported $1.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.03. The company had revenue of $11.54 billion during the quarter, compared to the consensus estimate of $11.59 billion. Novartis AG had a net margin of 13.10% and a return on equity of 15.46%. The firm’s revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.17 earnings per share. On average, equities analysts anticipate that Novartis AG will post $4.69 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Novartis AG (NVS) Given Consensus Rating of “Hold” by Analysts” was originally posted by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://baseballnewssource.com/markets/analysts-set-novartis-ag-nvs-price-target-at-80-42-updated-updated-updated/804387.html.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.